BLRX opened at $1.27 on Friday. BioLineRx has a fifty-two week low of $1.20 and a fifty-two week high of $3.73. The firm’s fifty day moving average price is $1.53 and its two-hundred day moving average price is $1.99. The company has a market capitalization of $60.55 million, a P/E ratio of -1.74 and a beta of 2.04.
BioLineRx (NASDAQ:BLRX – Get Rating) last posted its quarterly earnings results on Wednesday, March 16th. The biotechnology company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06. On average, analysts forecast that BioLineRx will post -0.56 earnings per share for the current fiscal year.
BioLineRx Company Profile (Get Rating)
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.
- Get a free copy of the StockNews.com research report on BioLineRx (BLRX)
- MarketBeat: Week in Review 5/2 – 5/6
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
- Peak Growth Is Over For Etsy
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.